Inmune Bio (INMB) Capital Expenditures (2025)

Inmune Bio (INMB) posted Capital Expenditures of $143000.0 for Q4 2025, down 25.91% sequentially from $193000.0 in Q3 2025.

Inmune Bio (INMB) Capital Expenditures (2025) Analysis & Trends

Inmune Bio has reported Capital Expenditures for 1 years, with the latest figure at $143000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Inmune Bio	61.59 Mn	43.18 Mn	-	-

Download Data